Tetrazine Cycloaddition Chemistry Balancing Reactivity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bioorthogonal cycloaddition reactions, such as SPAAC and IEDDA, either suffer from reduced reaction rates due to the use of non-strained alkyne or compromised reagent stability due to strained alkene, necessitating the development of non-strain-driven reactions that balance kinetics and stability for complex life systems.
Innovation Solution
A novel tetrazine compound with specific substituents (R1-C1-3 alkyl, R2-hydroxyl/C1-3 alkoxy, R3-H/C1-3 alkyl, R4-H/substituted phenyl) undergoes rapid cycloaddition with non-strained olefinic boronic acid, maintaining reagent stability and high reaction kinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If strained alkene is used in IEDDA reaction, then reaction kinetics are extremely fast, but reagent stability is compromised
Solution Approach 1:
The patent changes the reaction driver from strain promotion to electron-demand parameters. By using tetrazine with electron-withdrawing groups and non-strained olefinic boronic acid with electron-donating groups, the reaction is driven by electron demand rather than ring strain, achieving both fast kinetics and high stability
Solution Approach 2:
The patent introduces olefinic boronic acid as an intermediary reagent that combines the stability of non-strained olefins with the reactivity needed for bioorthogonal chemistry. The boronic acid group acts as a mediator that enables rapid cycloaddition without requiring strained alkene
2Object-affected harmful factors
If non-strained alkyne is used in SPAAC reaction, then toxicity is eliminated, but reaction rate is reduced
Solution Approach 1:
The patent replaces the mechanical strain-driven mechanism of SPAAC with an electron-demand driven mechanism. Instead of relying on ring strain to promote reaction, the system uses electronic properties (electron-withdrawing and electron-donating groups) to drive the cycloaddition, achieving faster rates without toxicity
Solution Approach 2:
The patent changes the reaction parameters from strain-promoted to electron-demand promoted. By adjusting the electronic properties of the reactants (tetrazine with electron-withdrawing groups and olefinic boronic acid with electron-donating groups), the reaction rate is enhanced while maintaining biocompatibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tetrazine compound exhibits good stability against biological thiols, easy availability of non-strained olefinic boronic acid, and high biocompatibility, enabling applications in biomedical fields like labeling, antibody-drug conjugates, and protein-targeted degradation.
Implementation Method 1
a novel tetrazine compound with high stability and good reactivity, and to develop a rapid cycloaddition reaction between the novel tetrazine compound and non-strained olefinic boronic acid
Data Source
AI summary
Disclosed are a tetrazine compound capable of having rapid cycloaddition reaction with non-strained olefinic boronic acid and biomedical application thereof. The present disclosure synthesizes a novel tetrazine compound capable of having rapid bioorthogonal cycloaddition reaction with non-strained olefinic boronic acid. The tetrazine compound of the present disclosure exhibits good stability, addressing the common contradiction in the stability and reactivity of a bioorthogonal reagent of a bioorthogonal reaction. A bioorthogonal cycloaddition reaction between the tetrazine compound of the present disclosure and non-strained olefinic boronic acid is characterized by readily available raw material, good biocompatibility, and high stability, and has great potential for application in the biomedical field of disease treatment, such as labeling, antibody-drug conjugates, prodrug release, and protein-targeted degradation.